---
figid: PMC5412337__ijms-18-00752-g001
figlink: /pmc/articles/PMC5412337/figure/ijms-18-00752-f001/
number: Figure 1
caption: 'Current strategies for targeting the epidermal growth factor receptor (EGFR)
  pathway. EGF receptors (Blue) activate survival signaling pathways including RAS/MAPK
  and PI3K/AKT signaling pathway leading to cell growth and proliferation. HGF/MET
  (green) signaling also promotes cell growth and proliferation through RAS/MAPK and
  STAT3 phosphorylation. Regular arrow: activates, Arrow ending with a straight line:
  inhibits.'
pmcid: PMC5412337
papertitle: Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment
  of Metastatic Colorectal Cancer.
reftext: Yuji Miyamoto, et al. Int J Mol Sci. 2017 Apr;18(4):752.
pmc_ranked_result_index: '4705'
pathway_score: 0.9362032
filename: ijms-18-00752-g001.jpg
figtitle: Current strategies for targeting the epidermal growth factor receptor (EGFR)
  pathway
year: '2017'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5412337__ijms-18-00752-g001.html
  '@type': Dataset
  description: 'Current strategies for targeting the epidermal growth factor receptor
    (EGFR) pathway. EGF receptors (Blue) activate survival signaling pathways including
    RAS/MAPK and PI3K/AKT signaling pathway leading to cell growth and proliferation.
    HGF/MET (green) signaling also promotes cell growth and proliferation through
    RAS/MAPK and STAT3 phosphorylation. Regular arrow: activates, Arrow ending with
    a straight line: inhibits.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAP2K1
  - MAP2K2
  - HGF
  - EGF
  - RAF1
  - BRAF
  - KRAS
  - ARAF
  - MTOR
  - HRAS
  - AKT3
  - AKT2
  - STAT3
  - AKT1
  - MET
  - NRAS
  - BMS-908662
  - Selumetinib
  - Tivantinib
  - Trametinib
  - Dabrafenib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: HGF
  symbol: HGF
  source: hgnc_symbol
  hgnc_symbol: HGF
  entrez: '3082'
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: STAT3
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MET
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
chemicals:
- word: BMS-908662
  source: MESH
  identifier: C000593770
- word: Selumetinib
  source: MESH
  identifier: C517975
- word: Tivantinib
  source: MESH
  identifier: C551661
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Dabrafenib
  source: MESH
  identifier: C561627
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
